Patents by Inventor Charles Francis Jewell, Jr.

Charles Francis Jewell, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ORGANIC COMPOUNDS
    Publication number: 20120142685
    Abstract: The present invention provides a compound formula I: (formula I) said compound is inhibitor of selective subset of kinases belonging to the AGC or calmodulin kinase family, such as for example MARK1/2/3, PKD-1/2/3, PKN-1/2, CDK-9, CaMKII, ROCK-I/II, inhibitors of histone deacetylase (HDAC) phosphorylation, or inhibitors of other kinases. Finally, the present invention also provides a pharmaceutical composition.
    Type: Application
    Filed: April 4, 2008
    Publication date: June 7, 2012
    Inventors: Markus Rolf Dobler, Charles Francis Jewell, JR., Erik Meredith, Lauren G. Monovich, Sarah Siska, Anette Von Matt, Maurice Van Eis, Taeyoung Yoon, Christoph Gaul, Michael Paul Capparelli
  • ORGANIC COMPOUNDS
    Publication number: 20110092505
    Abstract: The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 12, 2009
    Publication date: April 21, 2011
    Inventors: Robin Burgis, Michael Paul Capparelli, Lucian Dipietro, Gabriel G. Gamber, Charles Francis Jewell, JR., Erik Meredith, Karl Miranda, Lauren G. Monovich, Chang Rao, Nicolas Soldermann, Taeyoung Yoon, Qingming Zhu
  • 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives
    Patent number: 7291635
    Abstract: Compounds of the formula provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present invention may also be employed for inhibition of other enzymes with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula I may be employed for prevention or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels.
    Type: Grant
    Filed: April 2, 2003
    Date of Patent: November 6, 2007
    Assignee: Novartis AG
    Inventors: Gary Mark Coppola, John William Davies, Charles Francis Jewell, Jr., Yu-Chin Li, James Richard Wareing, Donald Mark Sperbeck, Travis Mathew Stams, Sidney Wolf Topiol, Isidoros Vlattas